UAE Adult Malignant Glioma Therapeutics Market Report 2022 to 2030

UAE Adult Malignant Glioma Therapeutics Market Analysis

$ 3999

The UAE Adult Glioma Therapeutics Market is valued at around $11 Mn in 2022 and is projected to reach $23 Mn by 2030, exhibiting a CAGR of 9.9% during the forecast period. The UAE Market is fuelled due to drivers like increasing partnerships with globally established firms and research institutions, an increased aging population and acceptance and investments in technological advancements by the government to decrease healthcare problems. Key players in the UAE Adult Malignant Glioma Therapeutics Market include companies like Arbor Pharmaceuticals, Amneal Pharmaceuticals, Karyopharm, Roche, Bio-Rad Laboratories, Azurity Pharmaceuticals and Merck & Co. among others.

ID: IN10AEPH426 CATEGORY: Pharmaceuticals GEOGRAPHY: UAE AUTHOR: Netal Patel

Buy Now

UAE Adult Malignant Glioma Therapeutics Market Executive Summary

The UAE Adult Glioma Therapeutics Market is valued at around $11 Mn in 2022 and is projected to reach $23 Mn by 2030, exhibiting a CAGR of 9.9% during the forecast period.

Adult malignant glioma is a kind of cancer that begins in the brain and is identified by the presence of malignant (cancerous) glial cells. In the central nervous system, glial cells surround and support neurons. Gliomas are tumors that arise from glial cells. Malignant gliomas are very aggressive and can spread to surrounding brain areas. Gliomas are brain tumours caused by glial cells, which are supporting cells in the central nervous system. Gliomas are classified based on the specific glial cell from which they originate and the level of malignancy. Astrocytomas, oligodendrogliomas, and ependymomas are only a few of the many forms. Glioblastoma multiforme (GBM), a kind of astrocytoma, is a rather prevalent disease in all gliomas.

The UAE's glioma treatment market has been predicted to have a glioma incidence rate of 0.56 per 100,000 people. This amounts to about 560 new glioma cases per year in the UAE, based on a 10 million population estimate in 2023. The UAE market is fueled by increasing partnerships with globally established firms and research institutions, an aging population, and government acceptance and investments in technological advancements to decrease healthcare problems.

Key players in the UAE Adult Malignant Glioma Therapeutics Market include companies like Arbor Pharmaceuticals, Amneal Pharmaceuticals, Karyopharm, Roche, Bio-Rad Laboratories, Azurity Pharmaceuticals, and Merck & Co., among others.

Market Dynamics

Market Growth Drivers

Collaboration with foreign pharmaceutical firms and research institutions allows for faster access to novel glioma medicines produced abroad. The UAE, a developing country, has made progress by learning from established markets. Sharing best practices and implementing successful techniques from nations with established glioma treatment programs may lead to the UAE market.

The treatment of gliomas is improved by utilizing contemporary technologies and methods. Newer technologies, such as genetic testing and tumour profiling, allow for personalized treatment programs based on individual tumour features, boosting efficacy and lowering adverse effects. Drugs that target particular glioma mutations provide a more precise and effective approach than conventional chemotherapy. Promising advances in immunotherapy, such as CAR-T cell therapy, have the potential to transform glioma treatment by leveraging the immune system.

Technological developments in glioma detection and analysis, including a rapid increase in innovative pipeline treatment candidates, are projected to fuel market expansion. Rising funding for research and development in the field of adult malignant glioma therapies is a major driver of market expansion.

Market Restraints

While the UAE's glioma therapeutics market holds promise, its growth faces several challenges. The prevalence of malignant gliomas in the UAE is low, which may hinder market expansion. Existing companies that are already competing in the market may act as huge barriers to entry into the market.

Strict restrictions and standards for the approval of new medications and therapies in the UAE may impede the adoption of newer treatments for adult malignant gliomas. This might slow market growth and limit patients' access to sophisticated therapy choices.

The UAE's reimbursement regulations may have an impact on the adoption of expensive and new treatments for adult malignant glioma. This may impede market expansion and patients' access to improved therapies.

Healthcare Policies and Regulatory Landscape

Healthcare policy and regulation in the UAE are defined by a strong, publicly funded health system and a rapidly rising private health business. The healthcare system is governed by federal and emirate rules, with public healthcare services managed by several regulatory agencies such as the Health Authority-Abu Dhabi (HAAD), the Dubai Health Authority (DHA), and the Emirates Health Authority (EHA), all under Ministry of Health and Prevention (MOHAP). To register new therapeutics in the UAE, the application must be made to the proper authorities along with the submission of extensive paperwork, including clinical trial data, to support their registration application. Once a drug is approved and registered for use in the UAE, the manner of dispensation is decided depending on the level of control in the source country and the amount of control of the active component under UAE legislation. Medication prices are established by UAE legislation, and the MOHP updates the pricing list regularly.

Competitive Landscape

Key Players

Arbor Pharmaceuticals
Amneal Pharmaceuticals
Karyopharm
Roche
Bio-Rad Laboratories
Azurity Pharmaceuticals
Merck & Co.
Mylan N.V.
Teva Pharmaceuticals
Pfizer

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

UAE Adult Malignant Glioma Therapeutics Market Segmentation

By Disease Type

Glioblastoma Multiforme
Anaplastic Astrocytoma
Anaplastic Oligodendroglioma
Anaplastic Oligoastrocytoma
Other Types

By Treatment Type

Chemotherapy
Targeted Drug Therapy
Radiation Therapy
Surgery
Gene Therapy
Immunotherapy
Vaccines

By Distribution Channel

Hospital Pharmacies
Drug Stores & Retail Pharmacies
Online Pharmacies

By Disease Stage

Early-Stage Tumour
Late-Stage Tumour
Palliative Care

By Route of Administration

Oral
Parenteral
Others

By End User

Hospitals
Speciality Clinics
Chemotherapy Centres
Radiotherapy Centres
Homecare
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.